Mesoblast’s Ryoncil ® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved ...
Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”) today announced that its wholly-owned subsidiary, Surgery Center Holdings, Inc. (the “Issuer”), priced $425.0 million ...
Terns Pharmaceuticals is a clinical-stage oncology company reimagining known biology to deliver high impact medicines. Our lead program TERN-701 is a highly selective, allosteric BCR-ABL inhibitor ...
U.S. Food and Drug Administration (FDA) approval of the Zenflow Spring ® Implant and Delivery System for the treatment of symptoms associated with benign prostatic hyperplasia (BPH), also known as ...
Leerink Partners and Piper Sandler are acting as joint bookrunning managers for the proposed offering.
The Coalition notes that the Ford government has been paying 20% more for each surgery in private cataract clinics and more than 200% more per surgery to the private hospital for which their former ...
WARREN, N.J., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today announced that its Founder and CEO, Dr. Ryan Saadi has donated 230,000 of his ...
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the ...
Prior to joining Serina, Dr. Thomas served in progressive scientific leadership roles at Mersana Therapeutics, where during his 13 years he played a pivotal part in building out their discovery ...
WEST VALLEY CITY, Utah, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Nusano, physics company working to transform radioisotope production and enable industries ranging from healthcare to nuclear energy, today ...
As we rapidly advance our co-lead programs through development, I’m pleased to announce this board transition at Oruka,” said Lawrence Klein, PhD, Chief Executive Officer of Oruka Therapeutics. “Chris ...
This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results